Mestag doses first patient in treatment for solid tumours
Mestag Therapeutics has dosed the first patient in its Phase I trial evaluating a novel therapeutic strategy to treat solid tumours.
MST-0312 is a bispecific antibody designed to activate lymphotoxin-beta receptor (LTBR) in the tumour microenvironment to induce the formation of tertiary lymphoid structures (TLS) and associated high endothelial venules (HEV) in tumour tissue.
The biotech company will evaluate MST-0312 in tumours formed in barrier organs such as the lung, gut, bladder, breast and skin, which are believed to be particularly sensitive to TLS formation.
The first-in-human trial is a multi-arm open-label study which will evaluate the safety, tolerability and efficacy of MST-0312 as a monotherapy and in combination with PD-1 inhibitor pembrolizumab.
“Dosing the first patient with MST-0312 is a significant milestone in developing this potential new therapeutic class,” said Dr Lindsey Rolfe, Chief Medical Officer of Mestag.
“Our carefully designed study evaluates monotherapy and combination therapy in immunologically ‘cold’ and ‘warm’ tumours, generating multiple mechanistic and clinical insights to inform future development. This important step reflects the scientific rigor and dedication of the Mestag team, as we advance novel therapies for patients.”
